Samuel Klein
Saint Louis, MONPI 1679590186
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $237,259 of the $295,469 with a category attached, or 80.3%. 22 manufacturers reported payments, led by Merck at 34.4% of the total.
Across 227 payments — averaging $1301.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$102K
- Boehringer Ingelheim$40K
- AbbVie$27K
- Novo Nordisk$25K
- Eli Lilly$24K
- Pfizer$22K
- plus $55K from 16 others
Across 5 payments — averaging $115,719 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$408K
- Janssen Research & Development, LLC$170K
- Novartis$417
- Dexcom, Inc.$180
What the payments were for
- Consulting fees$237,25980%
- Speaking & faculty fees$19,5957%
- Travel & lodging$33,36911%
- Food & beverage$5,2142%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 79 | $101,699 |
| Boehringer Ingelheim | 31 | $39,861 |
| AbbVie | 28 | $27,063 |
| Novo Nordisk | 15 | $24,735 |
| Eli Lilly | 25 | $24,431 |
| Pfizer | 3 | $22,301 |
| Regeneron | 20 | $20,108 |
| Madrigal Pharmaceuticals | 11 | $7,808 |
| Janssen Research & Development, LLC | 1 | $7,150 |
| Boehringer Ingelheim International GmbH | 1 | $5,600 |
| Astrazeneca UK Limited | 1 | $4,565 |
| Boehringer Ingelheim Mexico SA De CV | 1 | $3,750 |
| Medical Device Business Services, Inc. | 1 | $2,525 |
| Theratechnologies Inc. | 1 | $2,000 |
| Alnylam Pharmaceuticals Inc. | 2 | $1,480 |
| Dexcom, Inc. | 1 | $116 |
| Esperion Therapeutics, Inc. | 1 | $102 |
| AstraZeneca | 1 | $68 |
| La Jolla Pharmaceutical Company | 1 | $42 |
| BD | 1 | $28 |
| Amgen | 1 | $22 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$7,421
- JARDIANCE$3,750
- ECHELON ENDOPATH Stapler$2,525
- ENDOPATH XCEL Trocar Portfolio$2,525
- HARMONIC Product Family$2,525
- DEXCOM G6 TRANSMITTER$116
- NEXLIZET$102
- NEXLETOL$102
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.